Navigation Links
Anadys Pharmaceuticals to Present at BIO InvestorForum 2007
Date:10/3/2007

SAN DIEGO, Oct. 3 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will present at BIO InvestorForum 2007 on Wednesday, October 10, 2007, at 11:45 a.m. PDT (2:45 p.m. EDT). The conference is being held at The Palace Hotel in San Francisco.

Steve Worland, Ph.D., President and Chief Executive Officer of Anadys Pharmaceuticals, Inc. will present an overview of Anadys and an update on its two development-stage product candidates, ANA598 and ANA773.

The presentation will be simultaneously webcast and can be accessed on the Company's website at http://www.anadyspharma.com. Listeners are encouraged to visit the website approximately five minutes prior to the corporate presentation to download or install any necessary software. A replay of the presentation will be available approximately one hour after the live webcast concludes and will be archived until October 24, 2007.

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company committed to advancing patient care by developing and commercializing novel small molecule medicines for the treatment of hepatitis C virus (HCV) infection and cancer. The Company is developing ANA598, a small-molecule, non-nucleoside inhibitor of the NS5B polymerase for the treatment of HCV and ANA773, an oral TLR7 agonist prodrug for cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Anadys' strategy, development programs, and ability to develop and commercialize novel small molecule medicines for the treatment of HCV and cancer. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical studies may not be predictive of future results, and Anadys cannot provide any assurances that any of its product candidates will not have unforeseen safety issues, will have favorable results in future clinical trials or will receive regulatory approval. Risk factors that may cause actual results to differ are more fully discussed in Anadys' SEC filings, including Anadys' Form 10-K for the year ended December 31, 2006 and Anadys' Form 10-Q for the quarter ended June 30, 2007. All forward-looking statements are qualified in their entirety by this cautionary statement. Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.


'/>"/>
SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Supply of Radiopharmaceuticals Hampered by Attacks
2. FDA approves Watson Pharmaceuticals Oxytrol patch
3. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
4. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
5. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
6. Top Pharmaceuticals Influence Doctors Prescriptions
7. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
8. Personalized Medicine and Innovative Pharmaceuticals
9. New lease of life for asthmatics by Accentia Biopharmaceuticals
10. Pravastatin Launched by Watson Pharmaceuticals
11. Tata Industries picks up stake in Indigene Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... ... based oral and maxillofacial surgeon Dr. Majid Jamali is an expert in ... Dr. Jamali is proud to offer this permanent solution to patients who suffer from sleep ... This surgery is performed to correct the alignment of the jaw. It is beneficial for ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... Regenerative ... Best Places to Work employee satisfaction survey, earning them second place for Tampa’s Best ... with 25-49 employees. , “This is a great accomplishment for our team,” says ...
(Date:4/29/2016)... ... April 29, 2016 , ... International Dehydrated Foods, Inc. (IDF™) will attend and ... at the Doubletree by Hilton Hotel in Oak Brook, Illinois. The two-day event is ... for protein ingredients. , At the seminar, IDF™ will offer samples of its Savory ...
(Date:4/29/2016)... ... April 29, 2016 , ... The Society for Assisted Reproductive ... are required to report in vitro fertilization (IVF) delivery rates to ... practice of assisted reproductive technologies in the United States. , This year, ...
(Date:4/29/2016)... ... 29, 2016 , ... Orthodontics Limited, one of the nation’s ... Dr. Middleberg, were asked by Invisalign to present an “Ask the ... titled “Advancing the Biomechanics of Invisalign Clear Aligners,” Dr. Gemmi and Dr. Middleberg ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... 27, 2016 Transparency Market Research ... Market - Global Industry Analysis, Size, Share, Growth, Trends, ... the global skincare devices market was valued at US$ ... at a CAGR of 10.1% from 2015 to 2023 ... Browse the full Skincare Devices Market (Treatment Device - LED ...
(Date:4/27/2016)... April 27, 2016 ... the  "Global Anesthesia Disposables Market 2016-2020"  report ... ) ,The global anesthesia disposables market ... of 4.03% during the period 2016-2020.  ... threat to patients, safety. Organizations like the ...
(Date:4/26/2016)... Mich. , April 26, 2016 Diplomat ... promotion of Jennifer Hagerman , Pharm D., to ... her growing role at Diplomat, Hagerman will continue to ... the company that delivers custom education and training to ... the specialty pharmacy industry. Diplomat University also houses the ...
Breaking Medicine Technology: